FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2062702829> ?p ?o ?g. }

• W2062702829 endingPage "347" @default.
• W2062702829 startingPage "340" @default.
• W2062702829 abstract "Background and purposeAlthough FDG-avid tumors are recognized as a potential target for dose escalation, there is no clear basis for selecting a boost dose to counter this apparent radioresistance. Using a novel analysis method, based on the new concept of an outcome-equivalent dose, we estimate the extra dose required to equalize local control between FDG-avid and non-avid head and neck tumors.Materials and methodsBased on a literature review, five reports of head and neck cancer (423 patients in total), along with an internal validation dataset from our institution (135 oropharynx patients), were used in this analysis. To compensate for the heterogeneity among multi-institutional patient cohorts and corresponding treatment techniques, local control data of the cohorts were fit to a single dose–response curve with a clinically representative steepness (γ50 = 2), thereby defining an ‘outcome-equivalent dose’ (OED) for each institutional cohort. Separate dose–response curves were then determined for the FDG-avid and FDG-non-avid patient cohorts, and the ratio of TD50 (tumor dose required for 50% of control) values between the high- and low-FDG-uptake groups (TD50,high/TD50,low) was estimated, resulting in an estimated metabolic dose-modifying factor (mDMF) due to FDG-avidity.ResultsFor individual datasets, the estimated mDMFs were found to be in the range of 1.07–1.62, decreasing if the assumed slope (γ50) increased. Weighted logistic regression for the six datasets resulted in a mDMF of 1.19 [95% CI: 1.04–1.34] for a γ50 value of 2, which translates to a needed dose increase of about 1.5 Gy per unit increase in the maximum standardized uptake value (SUVm) of FDG-PET [95% CI: 0.3–2.7]. Assumptions of lower or higher γ50 values (1.5 or 2.5) resulted in slightly different mDMFs: 1.26 or 1.15, respectively. A validation analysis with seven additional datasets, based on relaxed criteria, was consistent with the estimated mDMF.ConclusionsWe introduced a novel outcome-equivalent dose analysis method to estimate the dose–response modifying effect of FDG uptake variation. To reach equal response rates, FDG-avid tumors are likely to require 10% to 30% more dose than FDG-non-avid tumors. These estimates provide a rational starting point for selecting IMRT boosts for FDG-avid tumors. However, independent tests and refinements of the estimated dose-modifying effect, using high-quality prospective clinical trial data, are needed." @default.
• W2062702829 created "2016-06-24" @default.
• W2062702829 creator A5026159944 @default.
• W2062702829 creator A5052610122 @default.
• W2062702829 creator A5076824413 @default.
• W2062702829 creator A5078855608 @default.
• W2062702829 creator A5080690685 @default.
• W2062702829 date "2014-06-01" @default.
• W2062702829 modified "2023-09-30" @default.
• W2062702829 title "Estimate of the impact of FDG-avidity on the dose required for head and neck radiotherapy local control" @default.
• W2062702829 cites W1965749846 @default.
• W2062702829 cites W1974031308 @default.
• W2062702829 cites W1974817010 @default.
• W2062702829 cites W1975501107 @default.
• W2062702829 cites W1976215126 @default.
• W2062702829 cites W1979087114 @default.
• W2062702829 cites W1986709694 @default.
• W2062702829 cites W1986947429 @default.
• W2062702829 cites W1991651174 @default.
• W2062702829 cites W1995799724 @default.
• W2062702829 cites W2000837444 @default.
• W2062702829 cites W2002022267 @default.
• W2062702829 cites W2015341124 @default.
• W2062702829 cites W2020645602 @default.
• W2062702829 cites W2028107411 @default.
• W2062702829 cites W2028760979 @default.
• W2062702829 cites W2029067546 @default.
• W2062702829 cites W2029657201 @default.
• W2062702829 cites W2037881077 @default.
• W2062702829 cites W2044190493 @default.
• W2062702829 cites W2052717355 @default.
• W2062702829 cites W2058810479 @default.
• W2062702829 cites W2059769860 @default.
• W2062702829 cites W2066210329 @default.
• W2062702829 cites W2068446009 @default.
• W2062702829 cites W2069240289 @default.
• W2062702829 cites W2072143869 @default.
• W2062702829 cites W2076660329 @default.
• W2062702829 cites W2084341371 @default.
• W2062702829 cites W2084681509 @default.
• W2062702829 cites W2086330889 @default.
• W2062702829 cites W2090337491 @default.
• W2062702829 cites W2092095921 @default.
• W2062702829 cites W2099281944 @default.
• W2062702829 cites W2104807192 @default.
• W2062702829 cites W2105656190 @default.
• W2062702829 cites W2120201677 @default.
• W2062702829 cites W2121932929 @default.
• W2062702829 cites W2123124107 @default.
• W2062702829 cites W2130503287 @default.
• W2062702829 cites W2136770345 @default.
• W2062702829 cites W2137716692 @default.
• W2062702829 cites W2140041771 @default.
• W2062702829 cites W2143967388 @default.
• W2062702829 cites W2145970993 @default.
• W2062702829 cites W2148433563 @default.
• W2062702829 cites W2154488733 @default.
• W2062702829 cites W2155491387 @default.
• W2062702829 cites W2161138187 @default.
• W2062702829 cites W2170821616 @default.
• W2062702829 cites W2092015632 @default.
• W2062702829 doi "https://doi.org/10.1016/j.radonc.2014.03.018" @default.
• W2062702829 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4822492" @default.
• W2062702829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24833560" @default.
• W2062702829 hasPublicationYear "2014" @default.
• W2062702829 type Work @default.
• W2062702829 sameAs 2062702829 @default.
• W2062702829 citedByCount "38" @default.
• W2062702829 countsByYear W20627028292014 @default.
• W2062702829 countsByYear W20627028292015 @default.
• W2062702829 countsByYear W20627028292016 @default.
• W2062702829 countsByYear W20627028292017 @default.
• W2062702829 countsByYear W20627028292018 @default.
• W2062702829 countsByYear W20627028292019 @default.
• W2062702829 countsByYear W20627028292020 @default.
• W2062702829 countsByYear W20627028292021 @default.
• W2062702829 countsByYear W20627028292022 @default.
• W2062702829 countsByYear W20627028292023 @default.
• W2062702829 crossrefType "journal-article" @default.
• W2062702829 hasAuthorship W2062702829A5026159944 @default.
• W2062702829 hasAuthorship W2062702829A5052610122 @default.
• W2062702829 hasAuthorship W2062702829A5076824413 @default.
• W2062702829 hasAuthorship W2062702829A5078855608 @default.
• W2062702829 hasAuthorship W2062702829A5080690685 @default.
• W2062702829 hasBestOaLocation W20627028291 @default.
• W2062702829 hasConcept C126322002 @default.
• W2062702829 hasConcept C141071460 @default.
• W2062702829 hasConcept C143998085 @default.
• W2062702829 hasConcept C151956035 @default.
• W2062702829 hasConcept C159654299 @default.
• W2062702829 hasConcept C179223381 @default.
• W2062702829 hasConcept C203014093 @default.
• W2062702829 hasConcept C2776530083 @default.
• W2062702829 hasConcept C2989005 @default.
• W2062702829 hasConcept C3018411727 @default.
• W2062702829 hasConcept C509974204 @default.
• W2062702829 hasConcept C58962609 @default.
• W2062702829 hasConcept C71924100 @default.

• next